Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 5 of 15

  1. WO46069

    Hoffmann-La Roche

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  2. XEN1101

    Xenon Pharmaceuticals

    Focal Epilepsy

    phase 3 small molecule active

    2 trials

  3. XEN496

    Xenon Pharmaceuticals

    Epilepsy

    phase 3 small molecule terminated

    2 trials

  4. XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  5. Xanomeline and Trospium Chloride Capsules

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  6. ZB020-03-001

    Zenas BioPharma

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  7. ZB203L01

    Zambon SpA

    Motor fluctuations in advanced Parkinson’s disease

    phase 3 small molecule active

    1 trial

  8. Zonisamide

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    1 trial

  9. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  10. bapineuzumab

    Pfizer

    Alzheimer Disease

    phase 3 small molecule terminated

    1 trial

  11. copolymer 1

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  12. dimethyl fumarate

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  13. gabapentin

    Pfizer

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial

  14. immune globulin

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  15. lamotrigine, 300 mg/day

    GlaxoSmithKline

    Epilepsy, Partial

    phase 3 small molecule completed

    1 trial

  16. mifepristone

    CORCEPT THERAPEUTICS INC

    Psychotic Depression

    phase 3 small molecule terminated

    1 trial

  17. perampanel

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    2 trials

  18. pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

  19. placebo

    Pfizer

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  20. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  21. vormatrogine

    Chongqing Precision Biotech Co., Ltd

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial

  22. 0.9% sodium chloride, GADOTERIC ACID

    Eli Lilly Co.

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  23. 1462rot25ct

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  24. 18870

    Disc Medicine

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    phase 2 small molecule active

    1 trial

  25. 18F-92

    The First People's Hospital of Lianyungang

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  26. 18FMC225_FPG

    Fondazione Telethon ETS

    depression

    phase 2 small molecule active

    1 trial

  27. 219867

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  28. 223646

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  29. 283PD201

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  30. 5-(1-(2-[18F] fluoroethoxy))-[3-(6 for Alzheimers Disease, sporadic Ce…

    Disc Medicine

    Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson

    phase 2 small molecule active

    1 trial

  31. 64042056ALZ2001

    Janssen-Cilag International N.V.

    Preclinical Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  32. A phase 2 trial assessing Ifenprodil as a ReM... for Multiple sclerosis

    Pari Pharma GmbH

    Multiple sclerosis

    phase 2 other active

    1 trial

  33. ABBV-552

    AbbVie

    Alzheimer's Disease (AD)

    phase 2 small molecule completed

    1 trial

  34. ACP-103

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  35. ACP-104

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  36. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial

  37. ACT16753

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  38. ACT16877

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  39. ACU193-201

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

  40. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  41. AH0003

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  42. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  43. AMBROXOL , Microcrystalline cellulose

    Disc Medicine

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  44. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  45. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  46. ARO-MAPT-SC

    Arrowhead Pharmaceuticals Ireland Limited

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  47. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  48. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.